Proprietary LabCorp Clinical Decision Support Report Improves Adherence to Chronic Kidney Disease Treatment Guidelines

BURLINGTON, N.C.--(BUSINESS WIRE)--Jan. 4, 2016-- Laboratory Corporation of America^® Holdings (LabCorp^®) (NYSE: LH) today announced the results of a recently published clinical research study that demonstrates improved physician adherence to chronic kidney disease (CKD) treatment guidelines through the use of LabCorp’s innovative clinical decision support (CDS) report. Treatment guidelines provide evidence-based information to help physicians and patients better manage diseases and chronic conditions. LabCorp’s CDS report presents the CKD guidelines information in an easy-to-use format with clear action steps for the physician and patient to follow.



Laboratory Corporation of America - Investor Relations - RSS Content